ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 120,80
-0,94%
Dow Jones
42 801,72
0,52%
DAX
23 008,94
-1,87%
Brent Oil
70,235
0,00%
Bitcoin
86 245,01
0,11%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Longeveron Inc (LGVN)

  7. Longeveron Inc (LGVN) Actualités

LGVN

Longeveron (LGVN)

Longeveron Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:LGVN
DateHeureSourceTitreSymboleSociété
05/03/202515h25GlobeNewswire Inc.Longeveron® to Present at the 37th Annual Roth ConferenceNASDAQ:LGVNLongeveron Inc
28/02/202522h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LGVNLongeveron Inc
28/02/202522h04GlobeNewswire Inc.Longeveron® Announces Full-Year 2024 Financial Results and Provides Business UpdateNASDAQ:LGVNLongeveron Inc
28/02/202522h00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LGVNLongeveron Inc
21/02/202514h30GlobeNewswire Inc.Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025NASDAQ:LGVNLongeveron Inc
18/02/202515h25GlobeNewswire Inc.Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™NASDAQ:LGVNLongeveron Inc
07/01/202501h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGVNLongeveron Inc
18/12/202415h10GlobeNewswire Inc.Longeveron to Present at Biotech Showcase 2025NASDAQ:LGVNLongeveron Inc
12/11/202422h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LGVNLongeveron Inc
12/11/202422h05GlobeNewswire Inc.Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:LGVNLongeveron Inc
11/11/202415h05GlobeNewswire Inc.Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)NASDAQ:LGVNLongeveron Inc
04/11/202422h05GlobeNewswire Inc.Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024NASDAQ:LGVNLongeveron Inc
29/10/202415h00GlobeNewswire Inc.Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)NASDAQ:LGVNLongeveron Inc
27/10/202420h10GlobeNewswire Inc.Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual MeetingNASDAQ:LGVNLongeveron Inc
14/10/202415h05GlobeNewswire Inc.Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)NASDAQ:LGVNLongeveron Inc
09/10/202415h05GlobeNewswire Inc.Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual MeetingNASDAQ:LGVNLongeveron Inc
07/10/202415h05GlobeNewswire Inc.Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy DayNASDAQ:LGVNLongeveron Inc
02/10/202415h05GlobeNewswire Inc.Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceNASDAQ:LGVNLongeveron Inc
26/09/202415h05GlobeNewswire Inc.Longeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the MesaNASDAQ:LGVNLongeveron Inc
03/09/202415h00GlobeNewswire Inc.Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)NASDAQ:LGVNLongeveron Inc
26/08/202422h05GlobeNewswire Inc.Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:LGVNLongeveron Inc
15/08/202412h08IH Market NewsCisco Beats Estimates and Announces Restructuring, Canoo Rises 6%, Lulus Losses Widen, Latest in EarningsNASDAQ:LGVNLongeveron Inc
14/08/202422h05GlobeNewswire Inc.Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:LGVNLongeveron Inc
14/08/202411h58IH Market NewsU.S. Futures Steady After Tuesday’s Strong Recovery; CPI in FocusNASDAQ:LGVNLongeveron Inc
05/08/202422h05GlobeNewswire Inc.Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024NASDAQ:LGVNLongeveron Inc
28/07/202422h51GlobeNewswire Inc.Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)NASDAQ:LGVNLongeveron Inc
19/07/202422h05GlobeNewswire Inc.Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:LGVNLongeveron Inc
18/07/202414h45GlobeNewswire Inc.Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:LGVNLongeveron Inc
17/07/202414h00GlobeNewswire Inc.Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s DiseaseNASDAQ:LGVNLongeveron Inc
10/07/202413h30GlobeNewswire Inc.Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s DiseaseNASDAQ:LGVNLongeveron Inc
 Showing the most relevant articles for your search:NASDAQ:LGVN

Dernières Valeurs Consultées

EU
EN
Bouygues
EU
RNO
Renault
EU
ORA
Orange
EU
BN
Danone
FTSE
UKX
FTSE 100
NYSE
DIS
Walt Disney
NASDAQ
NVDA
NVIDIA
NYSE
NKE
Nike
NASDAQ
AMZN
Amazon.com
SPI
SP500
S&P 500
EU
VK
Vallourec
EU
PX4
SBF 120
EU
SGO
Cie de SaintGobain
EU
AI
Air Liquide
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces